Prospective Assessment of Outcomes After Femoral Condyle Osteochondral Allograft Transplantation With Concurrent Meniscus Allograft Transplantation.

Background

Osteochondral allograft transplantation (OCAT) and meniscus allograft transplantation (MAT) have each become more commonly implemented for the treatment of young to middle-aged patients with complex knee pathology. Evidence regarding tibiofemoral OCAT in the setting of concurrent MAT is limited.

Purpose/Hypothesis

The purpose of this study was to characterize outcomes for femoral condyle OCAT with concurrent MAT (OCAT+MAT) in the ipsilateral compartment of patients after evidence-based shifts in practice. It was hypothesized that OCAT+MAT would be associated with successful outcomes characterized by statistically significant and clinically meaningful improvements in patient-reported outcome measures (PROMs) of knee pain and function in >80% of patients for at least 2 years after transplantation.

Study Design

Case series; Level of evidence, 4.

Methods

With institutional review board approval and documented informed consent, patients who underwent primary OCAT+MAT between 2016 and 2020 and enrolled in a lifelong registry for prospective collection of outcomes after OCAT were included. Patients with minimum 2-year follow-up data regarding complications, failures, adherence, and PROMs were analyzed. Patients who required OCAT and/or MAT revision or conversion to arthroplasty were defined as experiencing treatment failures.

Results

A total of 23 consecutive patients (mean age, 37.1 years; mean body mass index, 28 kg/m

Conclusion

OCAT+MAT was associated with successful short- to mid-term outcomes in 83% of cases. Evidence-based shifts in practice were implemented before the enrollment of this patient cohort. Older patients and those who were not adherent to postoperative restriction and rehabilitation protocols had a significantly higher risk for treatment failure and subsequent conversion to arthroplasty.

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

One or more of the authors has declared the following potential conflict of interest or source of funding: J.P.S. has received research support from Arthrex, the United States Department of Defense, and Thieme; education payments from Elite Orthopedics; consulting fees from Medical Device Business Services, Arthrex, DePuy Synthes, Orthopedic Designs North America, and Smith+Nephew; nonconsulting fees from Synthes GmbH and Medical Devices Business Services; and royalties from Thieme. C.W.N. has received research support from AO Foundation and Arthroscopy; education payments from Arthrex, Elite Orthopedics, and Medinc of Texas; consulting fees from Arthrex and Guidepoint Consulting; nonconsulting fees from Arthrex, Vericel, and Synthes GmbH; royalties from Arthroscopy; and hospitality payments from Stryker. J.L.C. has received research support from AO Trauma, Arthrex, Collagen Matrix, DePuy Synthes, MTF Biologics, Orthopaedic Trauma Association, Purina, Regenosine, SITES Medical, Thieme, and the United States Department of Defense; consulting fees from Arthrex and Trupanion; and royalties from Arthrex, MTF Biologics, and Thieme. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.